Tempus AI, Inc. Class A Common Stock

Tempus AI has received FDA 510(k) clearance for an AI-enabled software device that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension. The clearance adds pulmonary hypertension to Tempus' FDA-cleared cardiovascular AI products for atrial fibrillation and low ejection fraction. The company said the device is not intended to be a standalone diagnostic tool.

Tempus AI's chief legal officer Andrew Polovin sold 30,075 shares at $51.29 per share in a transaction totaling $1.5 million, according to an SEC filing. The sale was non-discretionary, executed to cover minimum statutory tax withholding obligations tied to the vesting of restricted stock units, and was conducted under a Rule 10b5-1 trading plan established on August 12, 2025. Following the disposition, Polovin retains 138,140 shares with an estimated market value of $8.5 million as of the August 19 close. Tempus AI shares have rallied about 75% since late last month, driven partly by a Moderna and Merck cancer vaccine trial hitting its endpoints, which validates the genomic sequencing technology behind Tempus's pending $1.5 billion Personalis deal. The company reported revenue up 22% to $382.5 million last quarter and its first GAAP profit.

Tempus AI shares jumped 39.5% after phase 3 INTerpath-001 trial results showed a customized mRNA-based melanoma treatment improved recurrence-free survival, alongside its pending US$1.50 billion acquisition of Personalis Inc. The trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. The Personalis deal would deepen Tempus AI's role in cancer genomics at the same time customized mRNA oncology approaches show clinical success, potentially strengthening the case that its data assets, assays, and AI tools are becoming more embedded in cutting edge oncology programs. Tempus AI's narrative projects $2.6 billion revenue and $13.4 million earnings by 2029, requiring 22.0% yearly revenue growth and roughly a $268 million earnings increase from -$254.4 million today. Some of the most optimistic analysts were already assuming revenue could reach about US$2.7 billion and earnings turn positive by 2029, and this new oncology trial result might eventually push those views even further apart.

Tempus AI reported second-quarter 2026 net income of US$5.64 million, swinging from a net loss of US$42.84 million a year ago, while revenue reached US$382.49 million. The company raised its full-year 2026 revenue guidance to between US$1.60 billion and US$1.61 billion. Tempus AI also announced a planned acquisition of Personalis to add cancer recurrence monitoring technology to its oncology and data platform. The return to profitability and higher outlook support the growth narrative, though risks around reimbursement and biopharma budgets remain.

Tempus AI has announced a research collaboration with Angiosarcoma Awareness, Inc. to apply its approximately 600 de-identified, molecularly sequenced angiosarcoma records and analytical resources to deepen understanding of this rare and aggressive cancer. The partnership creates one of the largest known angiosarcoma molecular datasets, offering researchers a more comprehensive view of disease biology and potential therapeutic opportunities. The initiative expands Tempus's rare cancer dataset and reinforces its data advantage, though it does not clearly change the immediate catalyst around improving adjusted EBITDA or the near-term risk of ongoing cash burn and pricing pressure from larger competitors. Tempus's narrative projects $2.4 billion revenue and $374.7 million earnings by 2029, requiring 20.8% yearly revenue growth and an earnings increase of about $677.6 million from negative $302.9 million today.

Tempus AI shares have fallen roughly 15% over the past year and about 4% year-to-date, even as the company reports strong revenue growth and expands its AI-powered precision medicine platform. In the most recent first quarter, revenue grew 36% year-over-year to $348.1 million, with its diagnostics business up 35% to $261.1 million and its Data and Applications segment up 40.5% to $87 million. Adjusted EBITDA loss narrowed to $2.8 million from $16.2 million in the prior quarter, and management expects positive adjusted EBITDA of $65 million in 2026. Wall Street analysts have a moderately bullish consensus, with an average price target of $65.62 implying 16% upside from current levels.

Tempus AI announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, a rare and aggressive cancer. The partnership will leverage Tempus' dataset of approximately 600 de-identified angiosarcoma records with paired DNA and RNA sequencing data, creating one of the largest known disease-specific molecular datasets for this cancer. Angiosarcoma is diagnosed in only about 1,000 people in the U.S. each year, and the initiative aims to identify biological patterns and potential therapeutic opportunities that are difficult to detect in smaller datasets. The collaboration builds on the Angiosarcoma Project launched in 2017 with the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Count Me In. Corrie Painter, CEO of Angiosarcoma Awareness, stated that combining Tempus' molecular and clinical oncology dataset with the patient-partnered resources from the Angiosarcoma Project could create an unprecedented view of the disease and establish a model for collaborative data sharing across rare cancers.

Tempus AI announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm. The study assessed the ECG-AF software across three geographically distinct clinical sites, analyzing data from 4,017 patients aged 65 and older without prior atrial fibrillation or pacemaker or defibrillator use. The company reported that the ECG-AI-derived risk score surpassed pre-specified performance thresholds, supporting its 2024 FDA clearance for the technology. Brandon Fornwalt, SVP of Cardiology at Tempus and coauthor, said the study marks an important step toward shifting cardiac care from late-stage intervention to early risk detection, and that the model consistently predicts atrial fibrillation across varied clinical environments.